Methoxyamine

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	CH5NO
Molecular Weight	47.0565
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CON

InChI

InChIKey=GMPKIPWJBDOURN-UHFFFAOYSA-N

InChI=1S/CH5NO/c1-3-2/h2H2,1H3

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23054206
Curator's Comment: The description was created based on several sources, including https://clinicaltrials.gov/ct2/show/NCT01851369 | https://www.ncbi.nlm.nih.gov/pubmed/29108368 | https://clinicaltrials.gov/ct2/show/NCT02395692 | https://www.ncbi.nlm.nih.gov/pubmed/28670521

Methoxyamine (TRC102) is an orally bioavailable small molecule with potential adjuvant activity, that may potentiate the antitumor activity of alkylating agents. Methoxyamine covalently binds to apurinic/apyrimidinic (AP) DNA damage sites and inhibits base excision repair (BER) that causes topoisomerase II-dependent irreversible strand breaks and apoptosis. Methoxyamine is currently being studied in multiple Phase 1 and Phase 2 clinical trials sponsored by the National Cancer Institute or Case Comprehensive Cancer Center.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA topoisomerase II 66 Target ID: CHEMBL2094255 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23054206	Inhibitor 8504
DNA topoisomerase II 66 Target ID: CHEMBL2094255 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23054206	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Respiratory tract infections 85 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7031458	Curative	Not Provided 511	Unknown Approved Use Unknown
Advanced peritoneal malignant mesothelioma 2 Sources: https://clinicaltrials.gov/ct2/show/NCT02535312	Primary	Phase II 1147	Unknown Approved Use Unknown
Advanced pleural malignant mesothelioma 2 Sources: https://clinicaltrials.gov/ct2/show/NCT02535312	Primary	Phase II 1147	Unknown Approved Use Unknown
Non-small cell lung cancer 211 Sources: https://clinicaltrials.gov/ct2/show/NCT02535312	Primary	Phase II 1147	Unknown Approved Use Unknown
Ovarian cancer 160 Sources: https://clinicaltrials.gov/ct2/show/NCT02535312	Primary	Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
64.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	30 mg/m² single, oral dose: 30 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
19.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	15 mg/m² single, oral dose: 15 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
126 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	30 mg/m² 1 times / day multiple, oral dose: 30 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
68.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	15 mg/m² 1 times / day multiple, oral dose: 15 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
327 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	60 mg/m² 1 times / day multiple, oral dose: 60 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
152 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	100 mg/m² single, oral dose: 100 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
119 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	60 mg/m² single, oral dose: 60 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
247 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	100 mg/m² 1 times / day multiple, oral dose: 100 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
1041 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	30 mg/m² single, oral dose: 30 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
287 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	15 mg/m² single, oral dose: 15 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1960 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	30 mg/m² 1 times / day multiple, oral dose: 30 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1136 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	15 mg/m² 1 times / day multiple, oral dose: 15 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5812 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	60 mg/m² 1 times / day multiple, oral dose: 60 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2312 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	100 mg/m² single, oral dose: 100 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1991 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	60 mg/m² single, oral dose: 60 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3105 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	100 mg/m² 1 times / day multiple, oral dose: 100 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
21.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	30 mg/m² single, oral dose: 30 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
37.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	15 mg/m² single, oral dose: 15 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
30.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	30 mg/m² 1 times / day multiple, oral dose: 30 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
41.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	15 mg/m² 1 times / day multiple, oral dose: 15 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
26.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	60 mg/m² 1 times / day multiple, oral dose: 60 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
26.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	100 mg/m² single, oral dose: 100 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
21.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	60 mg/m² single, oral dose: 60 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
25 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23054206	100 mg/m² 1 times / day multiple, oral dose: 100 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	METHOXYAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
100 mg/m2 1 times / day multiple, oral Highest studied dose Dose: 100 mg/m2, 1 times / day Route: oral Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/23054206	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/23054206	DLT: Anemia... Disc. AE: Anemia... Dose limiting toxicities: Anemia (grade 3, 50%) AEs leading to discontinuation/dose reduction: Anemia (grade 2-3, 66.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/23054206
60 mg/m2 1 times / day multiple, oral MTD Dose: 60 mg/m2, 1 times / day Route: oral Route: multiple Dose: 60 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/23054206	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/23054206	DLT: Anemia... Dose limiting toxicities: Anemia (grade 4, 9%) Sources: https://pubmed.ncbi.nlm.nih.gov/23054206

AEs

AE	Significance	Dose	Population
Anemia	grade 2-3, 66.7% Disc. AE	100 mg/m2 1 times / day multiple, oral Highest studied dose Dose: 100 mg/m2, 1 times / day Route: oral Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/23054206	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/23054206
Anemia	grade 3, 50% DLT	100 mg/m2 1 times / day multiple, oral Highest studied dose Dose: 100 mg/m2, 1 times / day Route: oral Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/23054206	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/23054206
Anemia	grade 4, 9% DLT, Disc. AE	60 mg/m2 1 times / day multiple, oral MTD Dose: 60 mg/m2, 1 times / day Route: oral Route: multiple Dose: 60 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/23054206	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/23054206

Sourcing

Vendor/Aggregator	ID	URL
abcr GmbH	AB482181	http://www.abcr.de/shop/en/AB482181
Acadechem	ACDS-028758	http://www.acadechemical.com/product/103457
Alichem	490022510	http://www.alichem.com/en/products/67-62-9.html
Ambinter	Amb13777310	http://www.ambinter.com/reference/13777310
Aurora Fine Chemicals LLC	A00.658.173	http://online.aurorafinechemicals.com/info?ID=A00.658.173
Aurora Fine Chemicals LLC	K02.871.539	http://online.aurorafinechemicals.com/info?ID=K02.871.539
BOC Sciences	67-62-9	https://www.bocsci.com/o-methylhydroxylamine-cas-67-62-9-item-31121.html
ChemMol	99122228	http://www.chemmol.com/chemmol/99122228.html
Chemspace	CSSB00000234925	https://chem-space.com/CSSB00000234925
eNovation Chemicals	D618697	http://www.enovationchem.com/productDetails.asp?productID=D618697
Hairui	HR101304	http://www.hairuichem.com/en/product/67-62-9.html
iChemical	EBD2321783	http://www.ichemical.com/products/67-62-9.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network	LN03244274	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN03244274
mcule	MCULE-1068458971	https://mcule.com/MCULE-1068458971/
MolPort	MolPort-001-786-611	https://www.molport.com/shop/molecule-link/MolPort-001-786-611
Sinfoo Biotech	S013101	http://www.sinfoobiotech.com/product/1016499
Smolecule	S564660	https://www.smolecule.com/products/s564660
THE BioTek	bt-363875	https://www.thebiotek.com/product/others/bt-363875
Vitas-M Laboratory	BBL028003	http://www.request.vitasmlab.biz/index.php?option=com_search_stk&Itemid=22&stk=BBL028003&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink
Vitas-M Laboratory	STL373472	http://www.request.vitasmlab.biz/index.php?option=com_search_stk&Itemid=22&stk=STL373472&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink

PubMed

Title	Date	PubMed
A rapid microwave-assisted derivatization of bacterial metabolome samples for gas chromatography/mass spectrometry analysis.	2010-06-15	19397887
Water deficit alters differentially metabolic pathways affecting important flavor and quality traits in grape berries of Cabernet Sauvignon and Chardonnay.	2009-05-08	19426499
Flame acceleration and the development of detonation in fuel-oxygen mixtures at elevated temperatures and pressures.	2009-04-30	18782653
O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib.	2009-04-21	19367283
Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers.	2009-03-15	19240165
Novel metabolites of amodiaquine formed by CYP1A1 and CYP1B1: structure elucidation using electrochemistry, mass spectrometry, and NMR.	2009-03	19074972
Metabolite profiling studies in Saccharomyces cerevisiae: an assisting tool to prioritize host targets for antiviral drug screening.	2009-01-30	19183481
Improper excess light energy dissipation in Arabidopsis results in a metabolic reprogramming.	2009-01-26	19171025
Influence of high dietary sodium intake on the functional subtypes of alpha-adrenoceptors in the renal cortical vasculature of Wistar-Kyoto rats.	2009-01	19302553
Metabolomics of the interaction between PPAR-alpha and age in the PPAR-alpha-null mouse.	2009	19357638
Characterization of leaf apoplastic peroxidases and metabolites in Vigna unguiculata in response to toxic manganese supply and silicon.	2009	19286915
Oxidized phospholipids as potential molecular targets for antimicrobial peptides.	2008-10	18440299
The mismatch repair-mediated cell cycle checkpoint response to fluorodeoxyuridine.	2008-09-01	18543256
Importance of tyrosine residues of Bacillus stearothermophilus serine hydroxymethyltransferase in cofactor binding and L-allo-Thr cleavage.	2008-09	18699779
[Effects of manumycin combined with methoxyamine on apoptosis in myeloid leukemia U937 cells].	2008-08	18710617
Chrysomelidial in the opisthonotal glands of the oribatid mite, Oribotritia berlesei.	2008-08	18618178
Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance.	2008-07	18430789
Ion trap MS/MS of intact testosterone and epitestosterone conjugates--adducts, fragile ions and the advantages of derivatisation.	2008-07	18384826
Excision repair is required for genotoxin-induced mutagenesis in mammalian cells.	2008-05	18332048
High quality metabolomic data for Chlamydomonas reinhardtii.	2008-04-28	18442406
Perceiving molecular evolution processes in Escherichia coli by comprehensive metabolite and gene expression profiling.	2008-04-10	18402659
Mutants of GABA transaminase (POP2) suppress the severe phenotype of succinic semialdehyde dehydrogenase (ssadh) mutants in Arabidopsis.	2008	18846220
Biocatalytic enantioselective synthesis of N-substituted aspartic acids by aspartate ammonia lyase.	2008	18844200
Transcriptomic and metabolite analyses of Cabernet Sauvignon grape berry development.	2007-11-22	18034876
Unbiased characterization of genotype-dependent metabolic regulations by metabolomic approach in Arabidopsis thaliana.	2007-11-21	18028551
Pharmacokinetic study of three cardiovascular drugs by high-performance liquid chromatography using pre-column derivatization with 9,10-anthraquinone-2-sulfonyl chloride.	2007-10-15	17766197
Well-defined polymers with activated ester and protected aldehyde side chains for bio-functionalization.	2007-10-08	17599628
Rapid quantification of urinary oxycodone and oxymorphone using fast gas chromatography-mass spectrometry.	2007-10	17988456
A screen for suppressors of gross chromosomal rearrangements identifies a conserved role for PLP in preventing DNA lesions.	2007-08	17696614
GC-MS analysis of multiply derivatized opioids in urine.	2007-08	17567826
Hexose-6-phosphate dehydrogenase modulates 11beta-hydroxysteroid dehydrogenase type 1-dependent metabolism of 7-keto- and 7beta-hydroxy-neurosteroids.	2007-06-27	17593962
Anaphylactic shock associated with cefuroxime axetil: structure-activity relationships.	2007-06	17488833
Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2c receptor agonist for the treatment of obesity: role of metabolic activation.	2007-06	17344339
Analysis of synthetic 19-norsteroids trenbolone, tetrahydrogestrinone and gestrinone by gas chromatography-mass spectrometry.	2007-05-25	16963059
Enantioselective oxidation of O-methyl-N-hydroxylamines using monoamine oxidase N as catalyst.	2007-04-21	17406697
The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target.	2007-04-03	17560642
Combined treatment with temozolomide and methoxyamine: blocking apurininc/pyrimidinic site repair coupled with targeting topoisomerase IIalpha.	2007-03-01	17332299
Ape1 regulates hematopoietic differentiation of embryonic stem cells through its redox functional domain.	2007-03-01	17053053
Role for DNA polymerase beta in response to ionizing radiation.	2007-02-04	17126614
Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide.	2007-01-01	17200364
A re-investigation of the path of carbon in photosynthesis utilizing GC/MS methodology. Unequivocal verification of the participation of octulose phosphates in the pathway.	2006-11	17149533
DNA polymerase-beta is expressed early in neurons of Alzheimer's disease brain and is loaded into DNA replication forks in neurons challenged with beta-amyloid.	2006-10-25	17065437
A stronger DNA damage-induced G2 checkpoint due to over-activated CHK1 in the absence of PARP-1.	2006-10	17102615
Base excision repair of both uracil and oxidatively damaged bases contribute to thymidine deprivation-induced radiosensitization.	2006-08-01	16863931
On systems and control approaches to therapeutic gain.	2006-04-25	16638124
Methoxyamine potentiates iododeoxyuridine-induced radiosensitization by altering cell cycle kinetics and enhancing senescence.	2006-04	16648559
CASPT2 study of the decomposition of nitrosomethane and its tautomerization reactions in the ground and low-lying excited states.	2006-02-03	16438510
Role of DNA polymerase theta in tolerance of endogenous and exogenous DNA damage in mouse B cells.	2006-02	16436048
Characterization of the aldehyde reactive probe reaction with AP-sites in DNA: influence of AP-lyase on adduct stability.	2006	16898421
Aliphatic amidase from Rhodococcus rhodochrous M8 is related to the nitrilase/cyanide hydratase family.	2005-11	16336190

Patents

Sample Use Guides

In Vivo Use Guide

Twenty-eight patients were treated with TRC102 at 15, 30, 60 or 100 mg/m2/d. The MTD was exceeded at 100 mg/m2/d due to grade 3 anemia in 50 % of patients.

Route of Administration: Oral

In Vitro Use Guide

The human colorectal cancer cell line, HT29 were used for activity evaluation. HT29 cells were cultured at a density of 2×104 per well in multiwell plates (24 wells/plate, SPL). After 24 hours, we treated the cells with different concentrations of 5-FU (5-Fluorouracil) (0, 1, 5, 10, 50, 100 µM) or Mx (Methoxyamine) (0, 1, 6, 30, 60, 120 mM). After 24 hours, cell viability was determined by the trypan blue dye exclusion assay.

Name

Type

Language

Methoxyamine

Systematic Name

English

O-METHYLHYDROXYLAMINE

Preferred Name

English

HYDROXYLAMINE, O-METHYL-

Systematic Name

English

Methoxyamine [WHO-DD]

Common Name

English

O-METHYLHYDROXYLAMINE [HSDB]

Common Name

English

METHOXYAMINE [MI]

Common Name

English

HYDROXYLAMINE METHYL ETHER

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C274